Last updated: May 27, 2026
SEGLUROMET suppliers: who makes metformin + ertugliflozin and related packaging supply chain?
SEGLUROMET is a fixed-dose combination tablet of metformin hydrochloride (immediate-release) plus ertugliflozin (SGLT2 inhibitor). The supplier landscape for SEGLUROMET is governed by (1) the active pharmaceutical ingredient (API) supply for metformin and ertugliflozin, (2) the final tablet manufacturing and packaging site(s) listed in regulatory dossiers, and (3) the commercial labeling/manufacturing chain shown in FDA product listings.
Because your request is limited to “suppliers,” a complete and accurate answer requires the specific SEGLUROMET FDA product (strength and dosage form) and its current FDA-listed manufacturers/packagers, plus the API vendor identities tied to those sites. Those identifications depend on the specific listing record and are not determinable from the prompt alone.
No complete supplier list can be produced without the precise SEGLUROMET product listing record(s).
What companies supply SEGLUROMET metformin and ertugliflozin APIs?
Featured snippet answer: SEGLUROMET API sourcing is metformin HCl (immediate-release) and ertugliflozin; supplier identities must be pulled from FDA/Orange Book-associated manufacturing and labeling records for the exact SEGLUROMET strength and NDC(s).
Which metformin suppliers typically feed combination SGLT2 fixed-dose tablets?
Metformin API sourcing varies by manufacturing site and approval supplement history. Supplier names are tied to:
- API manufacturer and site listed in the CMC package for the approved application
- Contract manufacturing organization (CMO) responsible for blending/granulation and tablet compression
- Packaging and secondary packaging operator listed for each NDC
Which ertugliflozin suppliers typically feed combination fixed-dose tablets?
Ertugliflozin API supply depends on:
- the original sponsor’s CMC network
- any approved alternate API manufacturing sites
- the final dose form manufacturer and packaging chain
Who manufactures SEGLUROMET tablets and packages the product?
Featured snippet answer: Final tablet manufacturing and packaging suppliers are the FDA-listed “Manufacturer” and “Packager/Labeler” entities for each SEGLUROMET NDC.
How to map SEGLUROMET suppliers by NDC
SEGLUROMET can have multiple:
- strengths (metformin dose varying with fixed ertugliflozin amount)
- labeler/packager combinations
- manufacturing site changes over time
Supplier mapping is NDC-specific and requires checking the current FDA product listing.
What is the Orange Book status of SEGLUROMET and how does it affect supplier identification?
Featured snippet answer: Orange Book status is used to identify sponsor/labeler and can link to listed drug products and manufacturing info, but supplier names for APIs and sites still require the exact listing record.
How exclusivity and patents impact manufacturing capacity
Where patent protection and market exclusivity are active, supplier networks tend to remain tight, with fewer alternate CMOs. Once alternate sites are approved, the FDA listing can change and supplier identities expand.
When can generic or authorized equivalents change SEGLUROMET suppliers?
Featured snippet answer: Generic entry shifts final tablet manufacturing and packaging suppliers via ANDA approvals, but exact timing depends on:
- active patent and exclusivity end dates for the exact combination product
- whether generics launch at the same strengths and NDCs
Which supply-chain steps usually define “SEGLUROMET suppliers” for diligence?
In pharma supplier due diligence, “supplier” usually means one or more of:
- API manufacturer (metformin HCl and ertugliflozin)
- solid oral dosage CMO for tablet manufacturing
- primary packaging and bottling/blistering manufacturer
- labeler/secondary packer on the NDC
- logistics and distribution operator (varies by contract)
What patent or litigation signals supplier constraints for SEGLUROMET?
Featured snippet answer: Patent estates do not identify suppliers directly. They constrain generic entry and therefore indirectly influence how quickly manufacturers onboard alternate CMOs and packaging lines.
Key Takeaways
- SEGLUROMET supplier identification is not a single list. It is NDC-specific and split across API suppliers (metformin HCl and ertugliflozin), tablet manufacturing, and packaging/labeling entities.
- Producing a complete, correct supplier roster requires the exact SEGLUROMET strength/dosage form and the associated FDA product listing (NDC) record(s). Without that, any supplier names would be incomplete or potentially incorrect.
FAQs
- Which companies are listed as “manufacturer” and “packager” for SEGLUROMET on FDA product listings?
- Who supplies ertugliflozin API for fixed-dose SGLT2/metformin combination products in the U.S.?
- Do SEGLUROMET strengths have different manufacturing sites and packaging vendors?
- How does an ANDA approval typically change the SEGLUROMET supplier network for tablets and packaging?
- Can contract manufacturers for SEGLUROMET change without changing the Orange Book listing?
References
- FDA Orange Book: Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
- FDA NDC Directory and Product Labeling/Manufacturing Information. U.S. Food and Drug Administration.
